Regulatory Post Marketing Surveillance Study on Nexavar®

Completed

Brief Summary: This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar

Detailed Description: The objectives of this surveillance are to identify problems/questions regarding the followings in the clinical practice of using Nexavar®.

1. Unknown adverse events (in particular, serious adverse events)

2. Identification of adverse events occurred in the real practice.

3. Factors that are considered to affect on safety.

4. Factors that are considered to affect on effectiveness

Recruitment & Eligibility

Inclusion Criteria

Patients with diagnosis of advanced RCC or HCC and decision taken by the physician to prescribe Nexavar.

Exclusion Criteria

Exclusion criteria must be read in conjunction with the local product information but patients who are participating in other interventional studies currently will be excluded.

Arm && Interventions

Group	Intervention	Description
Group 1	Sorafenib (Nexavar, BAY43-9006)	-

Primary Outcome Measures

Name	Time	Method
Adverse events collection	From start of treatment to 4 weeks after discontinuation of treatment

Secondary Outcome Measures

Name	Time	Method
Duration of treatment, dosage and indication	Whole treatment period
Tumor status	Whole treatment period
Performance status	Whole treatment period

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial